参附强心丸对慢性心力衰竭血管紧张素Ⅱ和脑钠素影响

Effects of Shenfu Qiangxin Pill on Angiotensin Ⅱ and Brain Natriuretic of Chronic Heart Failure Patients

目的:探讨参附强心丸对慢性心力衰竭(CHF)心功能及对血管紧张素Ⅱ和脑钠素的影响。方法:84例CHF患者随机分为治疗组对照组各42例。对照组采用西医常规治疗,治疗组在西医常规治疗的基础上加用参附强心丸。疗程12周。观察两组心功能分级、检测左室舒张末期内径(LVEDD)、左室舒张末期内径(LVEDD)、N-末端原脑利钠肽(NT-proBNP)及血管紧张素Ⅱ(AngⅡ)。结果:两组治疗后心功能均明显改善,治疗组在降低LVEDD及增加LVEF方面优于对照组(P<0.01);治疗组NT-proBNP、AngⅡ水平均低于对照组(P<0.01);治疗后治疗组MLHFQ评分低于对照组(P<0.01)。结论:参附强心丸能使CHF患者LVEF上升,减小LVEDD,明显改善心功能,提高患者生活质量,其作用机制可能是通过下调BNP和AngⅡ来实现的。

Objective ： To discuss the effect of Shenfu Qiangxin Pill on cardiac function, Angiotensin Ⅱ and brain sodi- um of chronic heart failure （CHF） patients. Methods ：84 patients with CHF were randomly divided into treatment group and control group （ n = 42）. The control group treated by routine Western medicine, and the treatment group was given Shenfu Qiangxin Pill on the basis of conventional Western medicine therapy. A course of treatment was 12 weeks. We ob- served the cardiac function classification, detection of left ventricular end - diastolic diameter （ LVEDD）, left ventricutar end- diastolic diameter （LVEDD）, N- terminal primitive brain natriuretic peptide （NT- proBNP） and Angiotensin Ⅱ （Ang Ⅱ ） of two groups. Results： After the treatment, heart functions of patients were significantly improved in both groups. LVEDD reducing and LVEF increasing in the treatment group were better than that in the control group （ P 〈 0.01 ）. The treatment group＇ s NT - proBNP and Ang Ⅱ levels were lower than those of the control group （ P 〈 0. 01 ）. Treatment group＇s MLHFQ score was lower than that of the control group after treatment （P 〈0.01 ）. Conclusion： Shenfu Qiangxin Pill can increase the LVEF and reduce LVEDD, significantly improve cardiac function and improve the patients quality of life. Its mechanism may be through reducing the BNP and Ang Ⅱ.